Definium Therapeutics, Inc.
NASDAQ: DFTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert Barrow
- Employees
- 74
- Headquarters
- New York, United States
- IPO year
- 2016
- Market cap
- $4.6B
- Website
- https://definiumtx.com
Loading DFTX…
Loading profile data…Frequently asked questions about DFTX
What does Definium Therapeutics, Inc. (DFTX) do?
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GA...
Where does DFTX trade?
Definium Therapeutics, Inc. (DFTX) trades on the NASDAQ Global Select.
What sector is DFTX in?
Definium Therapeutics, Inc. (DFTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Definium Therapeutics, Inc.?
Robert Barrow is the chief executive officer of Definium Therapeutics, Inc. (DFTX).
Where is Definium Therapeutics, Inc. headquartered?
Definium Therapeutics, Inc. is headquartered in United States.
Does DFTX pay a dividend?
Definium Therapeutics, Inc. (DFTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DFTX go public?
Definium Therapeutics, Inc. (DFTX) completed its initial public offering in 2016.